课题基金 / 基金详情

REGULAR AND SUSTAINED RELEASE SIMVISTATIN IN HYPERCHOLESTEROLEMIA

REGULAR AND SUSTAINED RELEASE SIMVISTATIN IN HYPERCHOLESTEROLEMIA
定期和持续释放辛维他汀治疗高胆固醇血症
批准号：
6116977
负责人：
D ROGER ILLINGWORTH
金额：
$3.13万
依托单位：
OREGON HEALTH & SCIENCE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6116977
关键词：
antihypercholesterolemic agent clinical research clinical trials drug screening /evaluation human subject human therapy evaluation hypercholesterolemia metabolism disorder chemotherapy slow release drug

项目摘要

项目成果

D ROGER ILLINGWORTH的其他基金

相似基金

相关文献

中文摘要
翻译
本研究将比较两种降脂药物的降血脂作用及对 西维他汀在目前批准的最大限度内的胆固醇稳态 常规剂量(每天40毫克)和三次较高剂量(每天80毫克) 和缓释制剂，每天160毫克，缓释 用于原发性高胆固醇血症患者的配方。在四点之后 每周饮食基线的患者将被分配到这四个组中的一个 以1：3：3：3的比例制备，为期24周。功效， 将对每种剂量方案的代谢影响和安全性进行评估。
英文摘要
This study will compare the hypolipidemic effects and influence on cholesterol homeostasis of simvistatin at the current maximal approved dose (40 mg per day) with three higher doses (80 mg per day) in regular and time-release formulations and 160 mg per day in a time-release formulation in patients with primary hypercholesterolemia. After a four week dietary baseline patients will be assigned to one of these four preparations in a ratio of 1:3:3:3 for a period of 24 weeks. Efficacy, metabolic effects and safety will be evaluated on each dose regimen.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effects of simvastatin on postprandial hyperlipidemia
SIMVASTATIN ON STEROID HORMONE PRODUCTION IN MEN WITH HYPERCHOLESTEROLEMIA
THE EFFECTS OF HIGH DOSE SIMVASTATIN IN PRIMARY HYPERCHOLESTEROLEMIA
METABOLIC STUDY ON THE HYPOLIPIDEMIC EFFECTS OF DRUGS WHICH INHIBIT CHOLESTEROL
海外基金